Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Injectable B12 has been used safely by doctors for decades and is one of the most common medical injections out there
The most common user-reported experience: Temporary skin dryness in week 1 (resolves by week 2) Occasional injection site redness (standard for any subQ peptide) Some users report increased hair growth, including in unintended areas at higher doses At doses above 34 mg/day, some protocols note headaches, but this is well above standard dosing
Spinal reflex activity: a marker for neuronal functionality after spinal cord injury
Some studies also show protective effects
Egrifta (tesamorelin) initial approval November 10, 2010
Cagrilintide has a half-life of about 78 days (roughly 159195 hours measured in a Phase 1b study), and tirzepatide about 5 days (approximately 120 hours)
